PET/MR in prostate cancer: Technical aspects and potential diagnostic value

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue SUPPL. 1, 2013, Pages

  Souvatzoglou, Michael ^a   Eiber, Matthias ^b   Martinez Moeller, Axel ^a   Fürst, Sebastian ^a   Holzapfel, Konstantin ^b   Maurer, Tobias ^a   Ziegler, Sibylle ^a   Nekolla, Stephan ^a   Schwaiger, Markus ^a   Beer, Ambros J ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Multimodal imaging; PET CT; PET MR; Prostate cancer

Indexed keywords

ARTICLE; BONE METASTASIS; CANCER RECURRENCE; CLINICAL EVALUATION; CLINICAL PROTOCOL; DIAGNOSTIC VALUE; HUMAN; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; METHODOLOGY; MULTIMODAL IMAGING; PREDICTIVE VALUE; PROSTATE TUMOR; REVIEW; PROCEDURES; PROSTATIC NEOPLASMS;

HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS;

EID: 84891586077     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2445-4     Document Type: Article

References (52)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374-403.
2. Freedland SJ, Presti Jr JC, Amling CL, Kane CJ, Aronson WJ, Dorey F, et al. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology. 2003;61(4):736-41.
3. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169(2):517-23.
4. Chism DB, Hanlon AL, Horwitz EM, Feigenberg SJ, Pollack A. A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59(2):380-5.
5. Smith RA, Cokkinides V, Eyre HJ. Cancer screening in the United States. 2007: a review of current guidelines, practices, and prospects. CA Cancer J Clin. 2007;57(2):90-104.
6. Souvatzoglou M, Gaertner FC, Schwarzenboeck S, Beer AJ, Schwaiger M, Krause BJ. PET/CT for the diagnosis, staging and restaging of prostate cancer. Imaging Med. 2011;3(5):571-85. Review.
7. Weber WA, Grosu AL, Czernin J. Technology insight: advances in molecular imaging and an appraisal of PET/CT scanning. Nat Clin Pract Oncol. 2008;5(3):160-70.
8. 11C-choline PET/ CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med. 2009;50(9):1394-400.
9. Giovacchini G, Picchio M, Coradeschi E, Bettinardi V, Gianolli L, Scattoni V, et al. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2010;37(2):301-9.
10. Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT. Imaging prostate cancer: a multidisciplinary perspective. Radiology. 2007;243(1):28-53. Review.
11. Beer AJ, Eiber M, Souvatzoglou M, Schwaiger M, Krause BJ. Radionuclide and hybrid imaging of recurrent prostate cancer. Lancet Oncol. 2011;12(2):181-91. Review.
12. Antoch G, Bockisch A. Combined PET/MRI: a new dimension in whole-body oncology imaging? Eur J Nucl Med Mol Imaging. 2009;36 Suppl 1:S113-20.
13. Schlemmer HP, Pichler BJ, Krieg R, Heiss WD. An integrated MR/ PET system: prospective applications. Abdom Imaging. 2009;34:668-74.
14. Kuhn FP, Crook DW, Mader CE, Appenzeller P, von Schulthess GK, Schmid DT. Discrimination and anatomical mapping of PETpositive lesions: comparison of CT attenuation-corrected PET images with coregistered MR and CT images in the abdomen. Eur J Nucl Med Mol Imaging. 2013;40(1):44-51.
15. Zaidi H, Ojha N, Morich M, Griesmer J, Hu Z, Maniawski P, et al. Design and performance evaluation of a whole-body ingenuity TF PET-MRI system. Phys Med Biol. 2011;56(10):3091-106.
16. Delso G, Fürst S, Jakoby B, Ladebeck R, Ganter C, Nekolla SG, et al. Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner. J Nucl Med. 2011;52:1914-22.
17. Martinez-Möller A, Souvatzoglou M, Delso G, Bundschuh RA, Chefd'hotel C, Ziegler SI, et al. Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data. J Nucl Med. 2009;50:520-6.
18. Schulz V, Torres-Espallardo I, Renisch S, Hu Z, Ojha N, Börnert P, et al. Automatic, three-segment, MR-based attenuation correction for whole-body PET/MR data. Eur J Nucl Med Mol Imaging. 2011;38:138-52.
19. Eiber M, Martinez-Möller A, Souvatzoglou M, Holzapfel K, Pickhard A, Löffelbein D, et al. Value of a Dixon-based MR/ PET attenuation correction sequence for the localization and evaluation of PET-positive lesions. Eur J Nucl Med Mol Imaging. 2011;38(9):1691-701.
20. Drzezga A, Souvatzoglou M, Eiber M, Beer AJ, Fürst S, Martinez- Möller A, et al. First clinical experience of integrated whole-body PET/MR: comparison to PET/CT in patients with oncological diagnoses. J Nucl Med. 2012;53:845-55.
21. Hofmann M, Bezrukov I, Mantlik F, Aschoff P, Steinke F, Beyer T, et al. MRI-based attenuation correction for whole-body PET/MRI: quantitative evaluation of segmentation- and atlas-based methods. J Nucl Med. 2011;52:1392-9.
22. Delso G, Martinez-Möller A, Bundschuh R, Ladebeck R, Candidus Y, Faul D, et al. Evaluation of the attenuation properties of MR equipment for its use in a whole-body PET/MR scanner. Phys Med Biol. 2010;55(15):4361-74.
23. Tellmann L, Herzog H, Quick HH, Bockisch A, Beyer T. The effect of MR surface coils on PET quantification in whole-body PET/MR: results from a pseudo-PET/MR phantom study. Med Phys. 2011;38(5):2795-805.
24. Gaertner FC, Beer AJ, Souvatzoglou M, Eiber M, Fürst S, Ziegler SI, et al. Evaluation of feasibility and image quality of 68Ga- DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors. Invest Radiol. 2013;48(5):263-72.
25. Souvatzoglou M, Eiber M, Takai T, Fuerst S, Drzezga A, Ziegler S, et al. Integrated simultaneous [11C]choline PET/MR in patients with prostate cancer. Comparison with PET/CT. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:S254. Abstract.
26. Martinez-Möller A, Eiber M, Nekolla SG, Souvatzoglou M, Drzezga A, Ziegler S, et al. Workflow and scan protocol considerations for integrated whole-body PET/MRI in oncology. J Nucl Med. 2012;53(9):1415-26.
27. Djavan B, RaveryV, ZlottaA, Dobronski P, Dobrovits M, FakhariM, et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol. 2001;166(5):1679-83.
28. Noguchi M, Stamey TA, McNeal JE, Yemoto CM. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. J Urol. 2001;166(1):104-9.
29. Hoeks CM, Barentsz JO, Hambrock T, Yakar D, Somford DM, Heijmink SW, et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology. 2011;261(1):46-66 Review
30. Delongchamps NB, Rouanne M, Flam T, Beuvon F, Liberatore M, Zerbib M, et al. Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2-weighted, dynamic contrast-enhanced and diffusion-weighted imaging. BJU Int. 2011;107(9):1411-8.
31. Souvatzoglou M, Weirich G, Schwarzenboeck S, Maurer T, Schuster T, Bundschuh RA, et al. The sensitivity of [11C]choline PET/CT to localize prostate cancer depends on the tumor configuration. Clin Cancer Res. 2011;17(11):3751-9.
32. Park H, Wood D, Hussain H, Meyer CR, Shah RB, Johnson TD, et al. Introducing parametric fusion PET/MRI of primary prostate cancer. J Nucl Med. 2012;53(4):546-51.
33. 11C-acetate PET/CT. Eur J Radiol. 2012;81(11):2966-72.
34. Pace L, Nicolai E, Aiello M, Catalano O, Salvatore M. Wholebody PET/MRI in oncology: current status and clinical applications. Clin Transl Imaging. 2013;I:31-44. doi:10.1007/s40336- 013-0012-4. Review.
35. Takei T, Souvatzoglou M, Beer AJ, Drzezga A, Ziegler S, Rummeny EJ, et al. A case of multimodality multiparametric 11Ccholine PET/MR for biopsy targeting in prior biopsy-negative primary prostate cancer. Clin Nucl Med. 2012;37(9):918-9.
36. Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [(68)Ga]galliumlabelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40(4):486-95.
37. Vargas HA,Wassberg C, Akin O, Hricak H. MR imaging of treated prostate cancer. Radiology. 2012;262(1):26-42. Review.
38. Cirillo S, Petracchini M, Scotti L, Gallo T, Macera A, Bona MC, et al. Endorectal magnetic resonance imaging at 1.5 T to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol. 2009;19(3):761-9.
39. 11C-choline- PET/CT. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:S174. Abstract.
40. Beresford MJ, Gillatt D, Benson RJ, Ajithkumar T. A systematic review of the role of imaging before salvage radiotherapy for postprostatectomy biochemical recurrence. Clin Oncol. 2010;22:46-55 Review.
41. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, Mason MD, et al. Guidelines on prostate cancer. European Association of Urology 2012. http://www.uroweb.org/gls/pdf/08%20Prostate%20Cancer-LR%20March%2013th%202012. pdf. Accessed 9 May 2013.
42. Eiber M, Beer AJ, Holzapfel K, Tauber R, Ganter C, Weirich G, et al. Preliminary results for characterization of pelvic lymph nodes in patients with prostate cancer by diffusion-weighted MRimaging. Invest Radiol. 2010;45:15-23.
43. Even-Sapir E. Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. J Nucl Med. 2005;46(8):1356-67.
44. Rybak LD, Rosenthal DI. Radiological imaging for the diagnosis of bone metastases. Q J Nucl Med. 2001;45(1):53-64.
45. Rosenthal DI. Radiologic diagnosis of bone metastases. Cancer. 1997;80(8 Suppl):1595-607.
46. Nakanishi K, Kobayashi M, Nakaguchi K, Kyakuno M, Hashimoto N, Onishi H, et al. Whole-body MRI for detecting metastatic bone tumor: diagnostic value of diffusion-weighted images. Magn Reson Med Sci. 2007;6:147-55.
47. 11C-choline PET/CT for detection of bone metastases. Radiology. 2008;249:1017-25.
48. 11C-choline-PET/CT and whole body-MRI for staging of prostate cancer. Nuklearmedizin. 2007;46:161-8.
49. Sieren JC, Ohno Y, Koyama H, Sugimura K, McLennan G. Recent technological and application developments in computed tomography and magnetic resonance imaging for improved pulmonary nodule detection and lung cancer staging. J Magn Reson Imaging. 2010;32(6):1353-69. Review.
50. Koyama H, Ohno Y, Kono A, Takenaka D, Maniwa Y, Nishimura Y, et al. Quantitative and qualitative assessment of non-contrastenhanced pulmonary MR imaging for management of pulmonary nodules in 161 subjects. Eur Radiol. 2008;18(10):2120-31.
51. Stolzmann P, Veit-Haibach P, Chuck N, Rossi C, Frauenfelder T, Alkadhi H, et al. Detection rate, location, and size of pulmonary nodules in trimodality PET/CT-MR: comparison of low-dose CT and Dixon-based MR imaging. Invest Radiol. 2013;48(5):241-6.
52. Bubendorf L, Schöpfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31(5):578-83.